Jade Biosciences, Inc. (NASDAQ:JBIO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO) have received an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $34.3333.

Several equities analysts have weighed in on the company. Wall Street Zen lowered Jade Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Guggenheim increased their target price on Jade Biosciences from $23.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, May 11th. BTIG Research increased their target price on Jade Biosciences from $28.00 to $39.00 and gave the company a “buy” rating in a research note on Monday, March 16th. Zacks Research raised Jade Biosciences from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th. Finally, HC Wainwright increased their target price on Jade Biosciences from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, April 27th.

Jade Biosciences Trading Up 0.5%

NASDAQ:JBIO opened at $23.46 on Friday. Jade Biosciences has a 1-year low of $6.57 and a 1-year high of $28.00. The business’s 50-day moving average price is $19.56 and its two-hundred day moving average price is $15.92. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -11.61 and a beta of 1.52.

Jade Biosciences (NASDAQ:JBIO) last released its earnings results on Thursday, May 7th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.05). Sell-side analysts predict that Jade Biosciences will post -2.43 earnings per share for the current year.

Institutional Investors Weigh In On Jade Biosciences

A number of hedge funds have recently modified their holdings of the business. RA Capital Management L.P. raised its position in shares of Jade Biosciences by 245.6% during the fourth quarter. RA Capital Management L.P. now owns 3,671,083 shares of the company’s stock worth $56,645,000 after purchasing an additional 2,608,757 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Jade Biosciences during the first quarter worth about $43,557,000. Baker BROS. Advisors LP acquired a new stake in shares of Jade Biosciences during the fourth quarter worth about $25,323,000. Remedium Capital Partners LLC acquired a new stake in shares of Jade Biosciences during the fourth quarter worth about $24,345,000. Finally, Avidity Partners Management LP raised its position in shares of Jade Biosciences by 24.3% during the fourth quarter. Avidity Partners Management LP now owns 1,400,708 shares of the company’s stock worth $21,613,000 after purchasing an additional 273,522 shares during the period.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.